AU2022374695A1 - Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis - Google Patents
Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis Download PDFInfo
- Publication number
- AU2022374695A1 AU2022374695A1 AU2022374695A AU2022374695A AU2022374695A1 AU 2022374695 A1 AU2022374695 A1 AU 2022374695A1 AU 2022374695 A AU2022374695 A AU 2022374695A AU 2022374695 A AU2022374695 A AU 2022374695A AU 2022374695 A1 AU2022374695 A1 AU 2022374695A1
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- coated
- hpmcas
- oral formulation
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPCT/EP2021/079584 | 2021-10-25 | ||
| PCT/EP2021/079584 WO2023072368A1 (en) | 2021-10-25 | 2021-10-25 | Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis |
| PCT/EP2022/079666 WO2023072878A1 (en) | 2021-10-25 | 2022-10-24 | Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022374695A1 true AU2022374695A1 (en) | 2024-03-21 |
Family
ID=78536154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022374695A Pending AU2022374695A1 (en) | 2021-10-25 | 2022-10-24 | Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250041228A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4312994A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024536609A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240093898A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118234489A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022374695A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3230682A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312176A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005076A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2023072368A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202402786B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297020A (en) | 2020-04-24 | 2022-12-01 | Dr Falk Pharma Gmbh | A systemic preparation of a pyridonone derivative related to tg2 |
| HRP20231072T1 (hr) | 2020-04-24 | 2023-12-22 | Dr. Falk Pharma Gmbh | Sustavna formulacija derivata piridinona za celijakiju |
| WO2025153465A1 (en) * | 2024-01-15 | 2025-07-24 | UCB Biopharma SRL | Method for the treatment of fibrotic-related disorder associated to ibd |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006052755A1 (de) * | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
| EP2687511A1 (de) * | 2012-07-17 | 2014-01-22 | Zedira GmbH | Pyridinonderivate als Gewebetransglutaminaseinhibitoren |
-
2021
- 2021-10-25 WO PCT/EP2021/079584 patent/WO2023072368A1/en not_active Ceased
-
2022
- 2022-10-24 CN CN202280071095.9A patent/CN118234489A/zh active Pending
- 2022-10-24 JP JP2024524678A patent/JP2024536609A/ja active Pending
- 2022-10-24 US US18/704,228 patent/US20250041228A1/en active Pending
- 2022-10-24 CA CA3230682A patent/CA3230682A1/en active Pending
- 2022-10-24 EP EP22809386.0A patent/EP4312994A1/en active Pending
- 2022-10-24 MX MX2024005076A patent/MX2024005076A/es unknown
- 2022-10-24 KR KR1020247017206A patent/KR20240093898A/ko active Pending
- 2022-10-24 AU AU2022374695A patent/AU2022374695A1/en active Pending
- 2022-10-24 IL IL312176A patent/IL312176A/en unknown
- 2022-10-24 WO PCT/EP2022/079666 patent/WO2023072878A1/en not_active Ceased
-
2024
- 2024-04-10 ZA ZA2024/02786A patent/ZA202402786B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL312176A (en) | 2024-06-01 |
| JP2024536609A (ja) | 2024-10-04 |
| KR20240093898A (ko) | 2024-06-24 |
| US20250041228A1 (en) | 2025-02-06 |
| WO2023072368A1 (en) | 2023-05-04 |
| WO2023072878A1 (en) | 2023-05-04 |
| CN118234489A (zh) | 2024-06-21 |
| EP4312994A1 (en) | 2024-02-07 |
| CA3230682A1 (en) | 2023-05-04 |
| ZA202402786B (en) | 2025-07-30 |
| MX2024005076A (es) | 2024-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101157220B1 (ko) | 리팍시민을 포함하는 위내성 약학적 제제 | |
| US20250041228A1 (en) | Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis | |
| SK18832000A3 (sk) | Entericky potiahnutá farmaceutická tableta a spôsob jej prípravy | |
| JP5671609B2 (ja) | ヒドロモルホンおよびナロキソンを含む医薬組成物 | |
| CN110664780B (zh) | 延迟释放型半胱胺珠粒调配物,以及其制备及使用方法 | |
| CN103269691A (zh) | 用于控制释放美沙拉嗪的口服药物片剂和其获得方法 | |
| CN101287443B (zh) | pH控制的脉冲释放系统、其制备方法和用途 | |
| EP2240166A2 (en) | Mesalazine tablet | |
| TW201742621A (zh) | 包含經黏膜黏附性材料包覆之個別核心單元之核心及核心腸衣之多單元劑型 | |
| WO2022245307A1 (en) | Composition of mesalazine enteric tablet formulation | |
| EP2533766B1 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
| US20050147663A1 (en) | Method of treatment for improved bioavailability | |
| US20100280035A1 (en) | Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier | |
| EA051945B1 (ru) | Пероральный препарат производного пиридинона и его применение для профилактики и/или лечения фиброза кишечника | |
| CN1835738A (zh) | 具有可膨胀的包衣的药物组合物 |